Bristol Myers Squibb Company $BMY Shares Sold by Courier Capital LLC

Courier Capital LLC lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 26.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 26,000 shares of the biopharmaceutical company’s stock after selling 9,523 shares during the period. Courier Capital LLC’s holdings in Bristol Myers Squibb were worth $1,622,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. Euro Pacific Asset Management LLC bought a new stake in shares of Bristol Myers Squibb in the third quarter valued at about $203,000. Sage Capital Advisors llc boosted its position in shares of Bristol Myers Squibb by 0.7% during the third quarter. Sage Capital Advisors llc now owns 88,538 shares of the biopharmaceutical company’s stock worth $5,525,000 after buying an additional 580 shares during the period. Steel Grove Capital Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 2.3% during the third quarter. Steel Grove Capital Advisors LLC now owns 34,186 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 758 shares in the last quarter. Sax Wealth Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 55.5% during the third quarter. Sax Wealth Advisors LLC now owns 10,357 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 3,695 shares in the last quarter. Finally, Fragasso Financial Advisors Inc raised its position in Bristol Myers Squibb by 7.8% in the 3rd quarter. Fragasso Financial Advisors Inc now owns 4,965 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 360 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Down 1.5%

Shares of Bristol Myers Squibb stock traded down $0.85 during trading hours on Tuesday, reaching $56.73. 16,958,086 shares of the company’s stock were exchanged, compared to its average volume of 12,081,742. The stock has a market cap of $115.89 billion, a P/E ratio of 12.50, a P/E/G ratio of 0.29 and a beta of 0.19. The company has a 50 day moving average of $63.99 and a two-hundred day moving average of $60.30. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.80 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RYZ101 delivered a significant Phase 3 win. RayzeBio’s radiopharmaceutical therapy met the primary endpoint in the ACTION-1 trial, producing a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced gastroenteropancreatic neuroendocrine tumors. The result supports discussions with regulators and strengthens BMY’s $4.1 billion radiopharmaceutical strategy. Bristol Myers Squibb Announces Positive Topline Results for RYZ101
• Positive Sentiment: Admilparant showed efficacy in idiopathic pulmonary fibrosis. The ALOFT-IPF Phase 3 trial met its primary endpoint at the 60-mg twice-daily dose, with reported clinical benefits and a favorable safety profile. The drug could address a serious chronic lung disease and provide a new growth opportunity for BMY. Bristol Myers Squibb Announces ALOFT-IPF Results
• Neutral Sentiment: The stock’s valuation remains a debate. BMY has gained roughly 38% over the past year, while analysts continue to view the shares as relatively inexpensive. However, the recent rally raises questions about whether current earnings and pipeline progress fully justify the valuation.
• Negative Sentiment: Mixed admilparant data limited the market’s reaction. Only the lower dose met the trial’s primary endpoint; the higher dose failed, creating uncertainty about the drug’s optimal dose and commercial potential. This prompted reports describing the results as “confounding” and contributed to BMY shares weakening after an initial positive response. Bristol Myers Admilparant Trial Results
• Negative Sentiment: Wells Fargo lowered its price target. The firm cut its target from $65 to $60 and maintained an “equal weight” rating, signaling limited near-term upside despite the trial announcements.
• Negative Sentiment: Upcoming earnings could add pressure. Analysts expect third-quarter earnings to decline by a single-digit percentage, keeping attention on BMY’s ability to offset generic competition and future patent-related revenue losses.

Analysts Set New Price Targets

Several equities research analysts have commented on BMY shares. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday. Daiwa Securities Group raised their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Leerink Partners downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $73.00 to $59.00 in a report on Monday, October 5th. Finally, Citigroup reissued a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $64.88.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.